ClinicalTrials.gg
RecruitingNCT05347238Updated Oct 16, 2026

Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis

An observational study in Late-Onset Neonatal Sepsis, Extreme Prematurity and Neonatal Hypotension, sponsored by Mount Sinai Hospital, Canada. Recruiting at 22 sites in 5 countries. Open to participants aged 21 Weeks to 32 Weeks. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Mount Sinai Hospital, Canada · Observational

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.
Updated Oct 16, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
550
Ages
21 Weeks to 32 Weeks
Sex
All
01

Study summary

Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring >48 hours of age). In Canada, \~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these \~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices.

Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS.

Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS.

Hypothesis: Primary treatment with NE will be associated with a lower mortality

Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 16 centers in Canada, 2 centers in Ireland, 1 center in each of Israel, Spain and the UK, and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved:

Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response

Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response

Read the detailed description

In this study, we will use real world data (RWD; defined as data generated during routine clinical practice) collected by our national Canadian Neonatal Network (CNN), which will be further expanded for this project.

The CNN is a well-established patient registry that includes members from 31 hospitals and 17 universities across Canada. The Network maintains a standardized NICU database and provides a unique opportunity for researchers to participate in collaborative projects. We will use the framework of Hypotheses Evaluating Treatment Effectiveness (HETE) research a form of comparative effectiveness research (CER).

Patient registries are emerging as a new method for assessment of treatments under the framework of CER. We will evaluate treatment effectiveness of two routinely used primary therapies for hypotension management in very preterm neonates with suspected LOS after standardizing treatment strategies and with a priori hypothesis.

02

Conditions studied

  • Late-Onset Neonatal Sepsis
  • Extreme Prematurity
  • Neonatal Hypotension

Browse trials for

03

In context

Neonatal Sepsis

193 studies on the registry are indexed under Neonatal Sepsis; 41 are open to participants now.

This study's planned enrollment of 550 is above the median of 200 across 85 observational studies indexed under Neonatal Sepsis.

Browse Neonatal Sepsis studies →

Lead sponsor

Mount Sinai Hospital, Canada is the lead sponsor of 158 studies on the registry; 32 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Weeks to 32 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All preterm infants born ≤32 weeks gestational age and > 48 hours of life with suspected sepsis with systemic hypotension admitted to the participating sites and meeting the above eligibility criteria will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≤32 weeks gestational age and > 48 hours of life
  • Receiving primary vasopressor therapy with Dopamine or Norepinephrine in the context of suspected late-onset sepsis or necrotizing enterocolitis with systemic hypotension (defined as: culture positive or negative bloodstream infection)

Exclusion criteria

Exclusion Criteria:

  • Known chromosomal or genetic anomalies
  • Receiving primary therapy with agents other than Dopamine or Norepinephrine
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
550 participants (estimated)
Target follow-up
36 Weeks
Patient registry
Yes

Groups and cohorts

  • Dopamine Units

    Units who have standardized their practice with the use of Dopamine as a first line agent.

    Drug: Dopamine

  • Norepinephrine Units

    Units who have standardized their practice with the use of Norepinephrine as a first line agent.

    Drug: Norepinephrine

Interventions

  • Start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response.

  • Start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response

06

What researchers measure

Primary outcomes

  1. All cause in-hospital mortality

    Death before discharge

    Time frame: From illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birth

Secondary outcomes

  1. Episode-related death

    Episode-related death (yes or no- binary variable)

    Time frame: <14 days from illness onset

  2. Treatment failure rate

    Need for further dose escalation or use of additional agents (treatment failure = hypotension unresolved after reaching max dose (15mics/kg/min in Dopamine units and 0.15 mics/kg/min in Norepinephrine units)

    Time frame: 90 minutes after initial vasopressor initiation (or sooner if secondary dose added or primary agent replaced as per clinical discretion)

  3. New diagnosis of severe neurological injury

    Grade III or Grade IV intraventricular hemorrhage or periventricular leukomalacia (yes or no- binary variable)

    Time frame: From illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birth

  4. Bronchopulmonary dysplasia

    Need for oxygen or positive pressure respiratory support at 36 weeks postmenstrual age (PMA) (yes or no- binary variable)

    Time frame: Assessed at 36 weeks PMA

  5. Retinopathy of prematurity

    Diagnosis of retinopathy of prematurity - assessed by clinical staff (yes or no - binary variable)

    Time frame: From illness onset to discharge (home or to another hospital) - assessed up to a maximum of 36 weeks after date of birth

  6. Length of hospital stay

    Length of entire neonatal intensive care unit stay from admission to discharge

    Time frame: From admission date to discharge date - assessed up to a maximum of 36 weeks after date of birth

07

Study locations

20 of 22 sites recruiting
  • Banner-University Medical Center Phoenix
    Phoenix, Arizona 85006, United States
    Not yet recruiting
    • Suma Rao · Contact
  • Dayton Children's Hospital
    Dayton, Ohio 45404, United States
    Recruiting
    • Shreyas Arya · Contact
  • Methodist Healthcare
    San Antonio, Texas 78229, United States
    Recruiting
    • Melissa Althouse, MD · Contact
  • Foothill's Medical Centre
    Calgary, Alberta, Canada
    Recruiting
    • Amuchou Soraisham · Contact
    • Amuchou Soraisham · Principal investigator
    • Essa El Awad · Sub investigator
    • Majeeda Kamaluddeen · Sub investigator
  • BC Women's Hospital
    Vancouver, British Columbia, Canada
    Recruiting
    • Michael Castaldo · Contact
    • Michael Castaldo · Principal investigator
  • Victoria General Hospital
    Victoria, British Columbia V8Z 6R5, Canada
    Recruiting
  • St.Boniface Hospital
    Winnipeg, Manitoba, Canada
    Not yet recruiting
    • Yasser ElSayed · Contact
    • Yasser ElSayed · Principal investigator
  • Winnipeg Health Sciences Centre
    Winnipeg, Manitoba, Canada
    Recruiting
    • Deepak Louis · Contact
    • Deepak Louis · Principal investigator
  • IWK Health Centre
    Halifax, Nova Scotia, Canada
    Recruiting
    • Walid El Naggar · Contact
    • Walid El Naggar · Principal investigator
  • McMaster Children's Hospital
    Hamilton, Ontario, Canada
    Recruiting
    • Amneet Sidhu · Contact
    • Amneet Sidhu · Principal investigator
  • London Health Sciences Centre
    London, Ontario, Canada
    Recruiting
    • Soume Bhattacharya · Contact
    • Soume Bhattacharya · Principal investigator
    • Renjini Lalitha · Sub investigator
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario, Canada
    Recruiting
    • Laurent Renesme · Contact
    • Laurent Renesme · Principal investigator
  • Hospital for Sick Children
    Toronto, Ontario, Canada
    Recruiting
    • Bonny Jasani · Contact
    • Bonny Jasani · Principal investigator
  • Mount Sinai Hospital
    Toronto, Ontario, Canada
    Recruiting
    • Laura Thomas, MSc · Contactlaura.thomas@sinaihealth.ca
    • Amish Jain · Principal investigator
    • Prakesh Shah · Sub investigator
    • Ashraf Kharrat · Sub investigator
    • Poorva Deshpande · Sub investigator
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
    Recruiting
  • Windsor Regional Hospital
    Windsor, Ontario, Canada
    Recruiting
    • Sajit Augustine · Contact
    • Sajit Augustine · Principal investigator
  • CHU Sainte- Justine
    Montreal, Quebec, Canada
    Recruiting
    • Anie Lapointe · Contact
    • Anie Lapointe · Principal investigator
    • Andreanne Villeneuve · Principal investigator
  • Jewish General Hospital
    Montreal, Quebec, Canada
    Recruiting
    • Nina Nouraeyan · Contact
    • Nina Nouraeyan · Principal investigator
  • Montreal Children's Hospital
    Montreal, Quebec, Canada
    Recruiting
    • Gabriel Altit · Contact
    • Gabriel Altit · Principal investigator
    • Marc Beltempo · Sub investigator
  • University Cork College
    Cork, Ireland
    Recruiting
    • Eugene Dempsey · Contact
  • Shamir Medical Center
    Be’er Ya‘aqov, Israel
    Recruiting
    • Sagee Nissimov · Contact
    • Sagee Nissimov, MD · Principal investigator
  • La Paz University Hospital
    Madrid, 28046, Spain
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 52 months after the start.

Of 37 non-industry observational studies under Neonatal Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 52 months is above that.

Counting every sponsor, half of 38 studies reached it within 28 months; a quarter within 16 and three quarters within 47.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Jun 2026 → Jun 2027 and completion Mar 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 26, 2022
StartActual
Feb 6, 2023
Primary completionEst.
Jun 30, 2027was Jun 2026
CompletionEst.
Mar 31, 2028was Mar 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Coombe Women & Infants University Hospital · Dublin, Ireland
Oct 16, 2026
Primary completion
Jun 30, 2026→Jun 30, 2027
Oct 16, 2026
Study completion
Mar 31, 2027→Mar 31, 2028
Oct 16, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • McMaster Children's Hospital · Hamilton, CanadaContact removed (no phone or email listed)
  • Sunnybrook Health Sciences Centre · Toronto, CanadaContact s•••@sunnybrook.ca→d•••@sunnybrook.ca
Oct 16, 2026
Sponsor
Collaborators removed: Coombe Women and Infants University Hospital·Children's Hospital at Montefiore·Golisano Children's Hospital
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site removed
    Show 1 removed
    • Coombe Women & Infants University Hospital · Dublin, Ireland
    Primary completion Jun 30, 2026→Jun 30, 2027
    Study completion Mar 31, 2027→Mar 31, 2028
    Sponsor Collaborators removed: Coombe Women and Infants University Hospital·Children's Hospital at Montefiore·Golisano Children's Hospital
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • McMaster Children's Hospital · Hamilton, CanadaContact removed (no phone or email listed)
    • Sunnybrook Health Sciences Centre · Toronto, CanadaContact s•••@sunnybrook.ca→d•••@sunnybrook.ca
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05347238
Collaborators
Sunnybrook Health Sciences Centre, The Hospital for Sick Children, London Health Sciences Centre, Windsor Regional Hospital, Foothills Medical Centre, Health Sciences Centre, Winnipeg, Manitoba, St. Boniface Hospital, Jewish General Hospital, St. Justine's Hospital, IWK Health Centre, University College Cork, Island Health, Victoria, BC, Assaf-Harofeh Medical Center, Dayton Children's Hospital, Banner University Medical Center, Methodist Healthcare - Memphis, Hospital Universitario La Paz, McMaster Children's Hospital, Children's Hospital of Eastern Ontario, BC Women's Hospital & Health Centre, Stony Brook University
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Feb 6, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Amish Jain, MBBS, MRCPCH, PhD
Contact
amish.jain@sinaihealth.ca
416-586-4800 ext. 5459
Laura Thomas, MSc
Contact
laura.thomas@sinaihealth.ca
416-586-4800 ext. 172060
Amish Jain, MBBS, MRCPCH, PhD
principal investigator · Mount Sinai Hospital, Canada

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion